Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Ophthalmic Solutions; Tetrahydrozoline; Travoprost

Criteria

Inclusion Criteria:

• Glaucoma or ocular hypertension in both eyes

• Currently being treated with latanoprost 0.005% daily and in need of additional IOP-lowering

• Best-corrected visual acuity of 20/100 or better in each eye

• Visual field within 6 months of study entry

Exclusion Criteria:

• Secondary glaucoma

• Active intraocular inflammation or macular edema

• Intraocular surgery or laser surgery within the past 3 months